Trevi Therapeutics, Inc.
Every calculator, already run for TRVI
Open the full toolkit →You have the numbers on TRVI. Get the argument.
A written report on which of these readings actually decide the outcome for Trevi Therapeutics, Inc., what has to stay true for the price to work, and the specific thing that would break it. The first one is free.
Key market data
Analyst consensus
10 analysts covering TRVIAnalyst Price Target Disagreement for Trevi Therapeutics, Inc.
Wall Street's bull case implies +193% from the current price; the bear case implies +69%. A 125% spread signals high analyst disagreement — run your own DCF to anchor on fundamentals rather than street consensus.
Ownership & short interest
Insider Trading Activity for TRVI
| Insider | Role | Type | Shares | Price | Value | Date | Filing |
|---|---|---|---|---|---|---|---|
About Trevi Therapeutics, Inc.
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes investigational therapy for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and non-IPF interstitial lung disease, and refractory chronic cough. The company develops Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER clinical trial for treatment of chronic cough in patients with IPF, and phase 2a clinical trial in patients with refractory chronic cough. Trevi Therapeutics, Inc. has a license agreement with Keenova Therapeutics plc to develop and commercialize products incorporating nalbup…
TRVI — frequently asked
Is TRVI a buy right now?
Wall Street's consensus rating on Trevi Therapeutics, Inc. is Strong Buy across 10 analysts, with a mean price target of $28.18 (+107% vs. the current $13.64). Ratings are a starting point — run the DCF and check the financial-health readings above before deciding.
When is TRVI's next earnings date?
Trevi Therapeutics, Inc. is next scheduled to report earnings around Nov 12, 2026. A full TRVI research report from Basis Report covers the setup into that print — estimates, the beat/miss record, and what would move the thesis.
What is the analyst price target disagreement for Trevi Therapeutics, Inc.?
Analysts covering Trevi Therapeutics, Inc. (TRVI) range from a bear-case target of $23.00 to a bull-case high of $40.00, with a mean consensus target of $28.18 across 11 analysts. The spread of $17.00 (125% of the current price) indicates high disagreement on the outlook. Run the DCF calculator to build your own estimate independent of street consensus.
Compare Trevi Therapeutics, Inc. against related stocks
Explore additional stock overview pages and jump directly into full report generation for each symbol.
Sector peers
Most-followed names in the same sector.
Nearby tickers
Additional public equities from our tracked universe.
Market leaders
Large-cap symbols investors frequently compare.
Investor Guides For Trevi Therapeutics, Inc.
Start with the evergreen guides that matter most for Healthcare, then move back into the ticker page when you want to pressure-test the framework on a live name.
Generate your full TRVI research report
DCF model, five-year financials, moat assessment, a BUY/HOLD/SELL rating, and the risks that matter — on Trevi Therapeutics, Inc., in minutes. 3 free reports included with every account — no credit card required.